Sanders Morris Harris LLC Makes New $5.08 Million Investment in uniQure N.V. $QURE

Sanders Morris Harris LLC bought a new position in uniQure N.V. (NASDAQ:QURE) in the third quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund bought 87,054 shares of the biotechnology company’s stock, valued at approximately $5,081,000. uniQure comprises about 0.7% of Sanders Morris Harris LLC’s portfolio, making the stock its 22nd largest position. Sanders Morris Harris LLC owned 0.16% of uniQure as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other institutional investors and hedge funds also recently made changes to their positions in the company. Tower Research Capital LLC TRC boosted its holdings in uniQure by 358.0% in the second quarter. Tower Research Capital LLC TRC now owns 7,085 shares of the biotechnology company’s stock valued at $99,000 after acquiring an additional 5,538 shares during the last quarter. KLP Kapitalforvaltning AS bought a new stake in uniQure during the 2nd quarter worth about $117,000. Teacher Retirement System of Texas acquired a new position in uniQure during the 2nd quarter valued at about $151,000. OMERS ADMINISTRATION Corp bought a new position in shares of uniQure in the 1st quarter valued at about $152,000. Finally, Mitsubishi UFJ Asset Management Co. Ltd. acquired a new stake in shares of uniQure during the 2nd quarter worth approximately $215,000. Institutional investors own 78.83% of the company’s stock.

Insider Buying and Selling

In related news, Director Robert Gut sold 31,434 shares of the company’s stock in a transaction dated Thursday, November 6th. The stock was sold at an average price of $27.26, for a total transaction of $856,890.84. Following the sale, the director owned 40,145 shares in the company, valued at approximately $1,094,352.70. This represents a 43.92% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, Director Jack Kaye sold 38,810 shares of the company’s stock in a transaction that occurred on Tuesday, November 4th. The stock was sold at an average price of $30.34, for a total value of $1,177,495.40. Following the sale, the director owned 20,439 shares in the company, valued at approximately $620,119.26. This represents a 65.50% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders have sold 314,560 shares of company stock worth $12,362,568 over the last 90 days. 4.79% of the stock is currently owned by insiders.

Wall Street Analysts Forecast Growth

QURE has been the subject of a number of analyst reports. Wall Street Zen lowered shares of uniQure from a “hold” rating to a “sell” rating in a report on Monday, December 8th. Benchmark reaffirmed a “buy” rating on shares of uniQure in a research note on Tuesday, November 4th. Guggenheim increased their target price on uniQure from $28.00 to $95.00 and gave the company a “buy” rating in a research note on Thursday, September 25th. Mizuho reduced their target price on uniQure from $60.00 to $33.00 and set an “outperform” rating on the stock in a report on Monday, December 8th. Finally, Chardan Capital reaffirmed a “buy” rating and issued a $53.00 price target on shares of uniQure in a research note on Thursday, December 4th. Ten equities research analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, uniQure currently has a consensus rating of “Moderate Buy” and a consensus target price of $60.82.

uniQure Stock Performance

Shares of QURE stock opened at $21.89 on Wednesday. The company has a debt-to-equity ratio of 0.23, a quick ratio of 7.12 and a current ratio of 7.12. uniQure N.V. has a 52 week low of $7.76 and a 52 week high of $71.50. The company’s 50 day moving average price is $39.59 and its two-hundred day moving average price is $26.52. The company has a market capitalization of $1.36 billion, a P/E ratio of -4.99 and a beta of 0.59.

uniQure (NASDAQ:QURE) last issued its quarterly earnings data on Monday, November 10th. The biotechnology company reported ($1.38) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.85) by ($0.53). The company had revenue of $3.70 million for the quarter, compared to the consensus estimate of $4.46 million. uniQure had a negative return on equity of 373.73% and a negative net margin of 1,492.90%. On average, analysts expect that uniQure N.V. will post -3.75 earnings per share for the current fiscal year.

uniQure Profile

uniQure N.V. develops treatments for patients suffering from rare and other devastating diseases. It offers HEMGENIX that has completed Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also develops AMT-130, a gene therapy that is in Phase I/II clinical study for the treatment of Huntington's disease.